ATYPICAL HEMOLYTIC UREMIC

Clinical trials for ATYPICAL HEMOLYTIC UREMIC explained in plain language.

Never miss a new study

Get alerted when new ATYPICAL HEMOLYTIC UREMIC trials appear

Sign up with your email to follow new studies for ATYPICAL HEMOLYTIC UREMIC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

Breakthrough drug trial offers hope for rare blood disorder patients in china

Disease control Completed

This study tested whether the drug eculizumab can control atypical hemolytic uremic syndrome (aHUS), a rare and serious blood disorder that can damage kidneys. The trial included 25 Chinese children and adults who had never received similar complement inhibitor treatments. Partic…

Matched conditions: ATYPICAL HEMOLYTIC UREMIC

Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control

Last updated Mar 30, 2026 14:35 UTC

ATYPICAL HEMOLYTIC UREMIC

Get alerted when new ATYPICAL HEMOLYTIC UREMIC trials appear

Breakthrough drug trial offers hope for rare blood disorder patients in china